Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs TG Therapeutics Inc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $81.26 (market cap $2.06B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 4× Global X Robo Global Robotics & Automation ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Robo Global Robotics & Automation ETF for 36 Days and TG Therapeutics Inc for 16 Days on average.
| ROBO | TGTX | |
|---|---|---|
Market Cap | $2.06B | $8.16B |
Volume | 148,111 | 1,735,121 |
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $59.06 |
52-Week Low | $63.04 | $26.94 |
Typical Hold Time | 36 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO trades at $81.26, down 0.68% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong institutional interest in robotics and AI themes, with recent news highlighting accelerating adoption across manufacturing, healthcare, and military applications. Financial ratios are unavailable in the current dataset.
The robotics sector offers long-term growth potential amid labor shortages and AI integration, though high RSI levels suggest near-term overbought conditions. Key risks include valuation concerns and sector competition, while analyst coverage remains favorable for diversified robotics exposure.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
